Edgewise Therapeutics, Inc.
EWTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,376 | $2,093 | $2,467 |
| - Cash | $46 | $43 | $50 | $42 |
| + Debt | $3 | $4 | $5 | $5 |
| Enterprise Value | – | $1,337 | $2,047 | $2,431 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$40 | -$42 | -$45 | -$45 |
| % Margin | – | – | – | – |
| Net Income | -$41 | -$36 | -$41 | -$40 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.39 | -0.34 | -0.43 | -0.42 |
| % Growth | -14.7% | 20.9% | -2.4% | – |
| Operating Cash Flow | -$35 | -$33 | -$38 | -$27 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$35 | -$33 | -$38 | -$27 |